Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.6K
Experimental RNAi02:15

Experimental RNAi

6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Sequential infection reprograms the immune landscape to shape future responses.

bioRxiv : the preprint server for biology·2026
Same author

Experimental change in temperament: Conversion of the low exploratory phenotype into highly explorative by overexpression of GDNF in the rat striatum.

Molecular psychiatry·2026
Same author

Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.

Pharmacological reviews·2026
Same author

Rapid Fragment Screening by <sup>19</sup>F Steady-State Free Precession NMR.

Angewandte Chemie (International ed. in English)·2026
Same author

Drugs targeting synaptic RNA m6A methylation regulate synaptic transmission and plasticity in the rat hippocampus.

Experimental neurology·2026

Related Experiment Video

Updated: May 30, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K

Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell

Vinicius Kannen1, Marit Rasmussen2, Siddhartha Das2

  • 1Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

Frontiers in Immunology
|January 27, 2025
PubMed
Summary

Removing PARP7 slows pancreatic cancer growth by boosting immune cell activity. This suggests targeting PARP7 could improve immunotherapy for pancreatic ductal adenocarcinoma (PDAC).

Keywords:
CRISPR/Cas9Poly-ADP-ribose polymerase 7pancreatic cancertumour infiltrating leukocytestype I interferon

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

Related Experiment Videos

Last Updated: May 30, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited treatment options.
  • Immunotherapy shows promise for PDAC by enhancing anti-tumour immunity.
  • PARP7, a negative regulator of the type I interferon (IFN-I) pathway, can suppress anti-tumour responses.

Purpose of the Study:

  • To investigate the role of PARP7 in pancreatic tumour growth.
  • To determine if targeting PARP7 can enhance anti-tumour immunity in PDAC.

Main Methods:

  • Utilized murine pancreatic cancer cells (CR705) and CRISPR/Cas9 gene editing.
  • Employed in vivo tumour models and spectral flow cytometry for analysis.
  • Conducted transcriptomic analyses and characterized tumour-infiltrating leukocytes (TILs).

Main Results:

  • Loss of Parp7 in cancer cells led to smaller tumour sizes in vivo.
  • Parp7 knockout cells showed elevated interferon stimulated gene factor 3 (ISGF3) activity.
  • Tumours lacking Parp7 exhibited increased infiltration of natural killer cells and CD8+ T cells, with fewer M2 macrophages, indicating an enhanced anti-tumour immune response.

Conclusions:

  • Loss of PARP7 inhibits PDAC tumour growth by promoting immune cell infiltration and enhancing anti-tumour immunity.
  • PARP7 inhibition represents a potential therapeutic strategy for PDAC treatment.
  • Targeting PARP7 may sensitize PDAC to immunotherapy.